Clinical trial NCT04986176: HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
Official title: HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: COVID-19 Respiratory Infection
Lead sponsor: Applied Biology, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Hinova Pharmaceuticals Inc.
First posted: 2021-08-02
Enrollment: 602
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective, superiority, interventional, placebo-controlled, double-blinded, randomized, parallel-assignment study
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.

Detailed description: This study is designed as a prospective, superiority, interventionist, placebo-controlled, double-blinded, randomized parallel assignment study. The study evaluates the efficacy and safety of HC- 1119.

Participants will be screened for eligibility; the assessment should be completed prior to any randomization to avoid screening failures to a maximum extent. Eligible participants (men and women) will be randomized 1:1 between arms (HC-1119 and placebo). HC-1119 and placebo will be administered orally.

The dosing regimen is 160 mg daily for 14 consecutive days. All patients will receive in parallel the standard treatment for COVID -19, according to the institution's protocol.

An electronic program will be used to manage randomization and drug shipment. The whole process will be handled in a manner that is blinded for the treatment received to all involved study personnel. The study follow up period will be 28 days after the first treatment.

Eligibility criteria: Inclusion Criteria:

1. Admitted to the hospital with symptoms of COVID-19.
2. Male and females age ≥18 years old.
3. Confirmed positive SARS-CoV-2, through existing RT-PCR test within 7 days prior to randomization.
4. Patients with clinical status categorized of scores 4, 5, or 6 on the COVID-19 Ordinal Scale:

   * 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID - 19 related or otherwise);
   * 5) Hospitalized, requiring supplemental oxygen;
   * 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices;
5. Participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo
6. Coagulation: INR ≤ 1.5 ×ULN, and APTT ≤ 1.5×ULN
7. Women of child-bearing potential must have negative results of plasma pregnancy test (serum HCG).
8. Participant (or legally authorized representative) gives written informed consent prior to performing any study procedures.
9. Participant (or legally authorized representative) agree that participant will not participate in another COVID-19 trial while participating in this study.

Exclusion Criteria:

1. Participant enrolled in another interventionist study for COVID -19 treatment.
2. Patients requiring mechanical ventilation.
3. Patients taking an anti-androgen of any type including: androgen depravation therapy, 5-alpha reductase inhibitors, etc, having last dose of treatment less than 3 months prior to screening.
4. Patients who are allergic to the investigational product or similar drugs (or any excipients).
5. Patients has malignant tumors in the past 5 years, except for completed resected basal cell and squamous cell skin cancer and completely resected carcinoma in situ of any type.
6. Patient with known serious cardiovascular disease:

   1. Heart Failure NYHA III.
   2. Heart Failure NYHA IV.
   3. Angina class III -Canadian cardiovascular Society.
   4. Angina class IV -Canadian cardiovascular Society
   5. Angina with recent onset of symptoms, whose symptoms started 30 days or less.
   6. Myocardial infarction the last 3 months.
   7. Stroke in the last 3 months.
7. Patient with a history of seizures/epilepsy.
8. Patient taking any medications (or combination of medications) that could induce seizures/epilepsy during the study period.
9. Patient with uncontrolled medical conditions despite adequate medication, that could compromise participation in the study (e.g., uncontrolled hypertension, hypothyroidism, diabetes mellitus).
10. Known diagnosis of human immunodeficiency virus (HIV), hepatitis C, active hepatitis B, treponema pallidum (testing is not mandatory).
11. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \> 5 times the upper limit of normal.
12. Estimated glomerular filtration rate (eGFR) \< 30 ml/min.
13. Severe kidney disease requiring dialysis.
14. Patient likely to transfer to another hospital within 28 days after hospitalization.
15. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless using a highly effective method of contraception (detailed in the study protocol) throughout the study and for 3 months after stopping treatment with HC-1119.
16. Sexually active men who refuse to use a condom during intercourse while taking HC-1119 and for 3 months after stopping treatment.
17. Pregnant, breastfeeding, or women planning to become pregnant 3 months after treatment with HC-1119
18. Participant (or legally authorized representative) not willing or unable to provide informed consent

Primary outcomes:
measure: All-cause mortality risk ratio assessed by the proportion of patient deaths in both study arms.
timeFrame: 28 days
Secondary outcomes:
measure: Recovery ratio assessed by measuring the proportion of recovered patients in both study arms.
timeFrame: 28 days
measure: Recovery ratio assessed by measuring the proportion of recovered patients in both study arms.
timeFrame: 14 days
measure: Post-randomization time to recover/alive hospital discharge assessed by the median days (interquartile range) of time to recover.
timeFrame: 28 days
measure: Hazard ratio for death assessed by measuring the proportion of deaths by time in both study arms.
timeFrame: 28 days
measure: Pharmacokinetics of HC-1119 assessed by area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)
timeFrame: 14 days
measure: Pharmacokinetics of HC-1119 assessed by area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration (AUC 0-t)
timeFrame: 14 days
measure: Pharmacokinetics of HC-1119 assessed by peak concentration (Cmax)
timeFrame: 14 days
measure: Pharmacokinetics of HC-1119 assessed by peak time (Tmax)
timeFrame: 14 days
measure: Pharmacokinetics of HC-1119 assessed by elimination half-life (t 1/2)
timeFrame: 14 days
measure: Efficacy of concomitant therapies assessed by sensitivity analysis of the primary, and key secondary outcomes.
timeFrame: 28 days
Other outcomes:
Locations:
Study officials:
References: